Scarica l'app Stockscreener
81.48
0.55%
-0.45
Dopo l'orario di chiusura:
81.48
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Precedente Chiudi:
$81.93
Aprire:
$82.41
Volume 24 ore:
1.44M
Relative Volume:
0.80
Capitalizzazione di mercato:
$9.66B
Reddito:
$1.51B
Utile/perdita netta:
$348.84M
Rapporto P/E:
29.30
EPS:
2.7805
Flusso di cassa netto:
$667.65M
1 W Prestazione:
+5.69%
1M Prestazione:
+8.70%
6M Prestazione:
+16.04%
1 anno Prestazione:
+39.90%
Intervallo 1D:
$81.46
$83.50
Intervallo di 1 settimana:
$76.82
$83.50
Portata 52W:
$57.67
$83.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Nome
Halozyme Therapeutics Inc
Settore
Industria
Telefono
(858) 794-8889
Indirizzo
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
81.48 | 9.72B | 1.51B | 348.84M | 667.65M | 2.7805 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-04 | Downgrade | Goldman | Neutral → Sell |
| 2025-10-14 | Aggiornamento | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-05-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Downgrade | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Iniziato | TD Cowen | Outperform |
| 2023-07-24 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Berenberg | Buy |
| 2023-03-16 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Ripresa | Morgan Stanley | Overweight |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Iniziato | Evercore ISI | Outperform |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Reiterato | The Benchmark Company | Buy |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | The Benchmark Company | Buy |
| 2020-02-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Buy |
| 2019-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Ripresa | Piper Jaffray | Neutral |
| 2018-05-11 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2017-10-16 | Reiterato | Piper Jaffray | Overweight |
| 2017-01-06 | Downgrade | Citigroup | Buy → Neutral |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-11-18 | Iniziato | Citigroup | Buy |
| 2015-09-22 | Iniziato | Barclays | Overweight |
| 2015-06-22 | Reiterato | JP Morgan | Overweight |
| 2015-03-03 | Reiterato | UBS | Buy |
| 2015-02-18 | Reiterato | MLV & Co | Buy |
| 2015-01-08 | Reiterato | MLV & Co | Buy |
Mostra tutto
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Halozyme Therapeutics Inc (HALO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
HALO|Halozyme Therapeutics Inc|Price:81.930|Chg%:+1.090 - TradingKey
Halozyme Therapeutics (RV7) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (HALO) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (HALO) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics, Inc. Revenue Breakdown – BX:RV7 - TradingView
Halozyme Therapeutics (HALO) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (HALO) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics, Inc. (HALO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Halozyme Therapeutics (HALO) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics, Inc. (HALO) stock price, news, quote and history - Yahoo Finance Australia
Halozyme Therapeutics (HALO) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (HALO) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics, Inc. (HALO) Options Chain - Yahoo! Finance Canada
HALO5638653 Bond Profile — Key Metrics - TradingView
HALO5638653 Bond Coupon Profile — Rate & Payments - TradingView
Halozyme Therapeutics stock hits all-time high at 82.42 USD - Investing.com
Halozyme Therapeutics Inc (HALO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Halozyme Therapeutics to report Q2 2026 results on August 6 - scanx.trade
Halozyme to host Aug. 6 call on second-quarter results - Stock Titan
Halozyme to report Q2 results after market close, host conference call - Bitget
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Phathom Pharmaceuticals (PHAT) and Incyte (INCY) - The Globe and Mail
Halozyme Therapeutics (HALO) Lands Incyte Deal On A Valuation That Still Looks Undervalued - Sahm
Halozyme’s Partnerships, Earnings Growth See Shares Near All-Time Highs - Yahoo Finance
Should Halozyme’s New ENHANZE–Incyte Oncology Pact Reshape How HALO Investors View Its Royalty Model? - Sahm
Benchmark reiterates Halozyme stock Buy rating on Incyte deal - Investing.com UK
Benchmark reiterates Halozyme stock Buy rating on Incyte deal By Investing.com - Investing.com South Africa
Did Halozyme’s (HALO) New Incyte Enhanze Deal Just Redefine Its Precision Oncology Royalty Engine? - Yahoo Finance
HALO Inks Deal With INCY to Support Cancer Therapy Development - Yahoo Finance
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE Technology - marketscreener.com
HALO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $95 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on Halozyme deal By Investing.com - Investing.com Canada
Halozyme (HALO) Partners with Incyte to Advance Drug Delivery Te - GuruFocus
Halozyme and Incyte sign licence agreement for INCA033989 formulations - Yahoo Finance
Halozyme Therapeutics (HALO) Secures Global Deal with Incyte for Innovative Drug Delivery - GuruFocus
Halozyme enters license agreement with Incyte - The Pharma Letter
Halozyme, Incyte to Collaborate on Development of Subcutaneous mAb Formulations - Contract Pharma
Halozyme and Incyte announce global collaboration deal - grafa.com
Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development - Yahoo Finance
Halozyme (HALO) Partners with Incyte to Advance Drug Delivery Technology - GuruFocus
Halozyme partners with Incyte on drug delivery technology - Investing.com
Halozyme partners with Incyte on drug delivery technology By Investing.com - Investing.com South Africa
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology - PR Newswire
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Booming Biotech with a 42.2% Revenue Growth - DirectorsTalk Interviews
Halozyme partners with Incyte to evaluate subcutaneous formulations - scanx.trade
Technical Reactions to HALO Trends in Macro Strategies - Stock Traders Daily
Halozyme Therapeutics (HALO) Gets A Lift As Darzalex Faspro Trial Improves Survival - Sahm
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
Halozyme Therapeutics (0J2O) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (0J2O) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (0J2O) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):